Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
3.85
Dollar change
+0.23
Percentage change
6.35
%
Index- P/E- EPS (ttm)-0.88 Insider Own42.41% Shs Outstand83.62M Perf Week11.92%
Market Cap380.19M Forward P/E- EPS next Y-0.58 Insider Trans0.00% Shs Float56.87M Perf Month19.94%
Income-74.24M PEG- EPS next Q-0.11 Inst Own30.73% Short Float1.17% Perf Quarter19.94%
Sales0.00M P/S- EPS this Y13.73% Inst Trans0.99% Short Ratio4.44 Perf Half Y19.94%
Book/sh1.75 P/B2.20 EPS next Y27.85% ROA-40.66% Short Interest0.67M Perf Year61.09%
Cash/sh0.88 P/C4.35 EPS next 5Y- ROE-44.93% 52W Range1.78 - 5.14 Perf YTD-23.00%
Dividend Est.- P/FCF- EPS past 5Y-13.66% ROI-53.27% 52W High-25.10% Beta1.02
Dividend TTM- Quick Ratio7.36 Sales past 5Y306.71% Gross Margin- 52W Low116.29% ATR (14)0.31
Dividend Ex-Date- Current Ratio7.36 EPS Y/Y TTM5.77% Oper. Margin-7376960.89% RSI (14)60.04 Volatility11.10% 9.21%
Employees156 Debt/Eq0.02 Sales Y/Y TTM-99.97% Profit Margin-7157319.53% Recom1.00 Target Price10.46
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-20.99% Payout- Rel Volume0.62 Prev Close3.62
Sales Surprise-100.00% EPS Surprise-692.26% Sales Q/Q-100.00% EarningsNov 03 BMO Avg Volume150.57K Price3.85
SMA2022.01% SMA501.21% SMA20024.48% Trades Volume93,145 Change6.35%
Date Action Analyst Rating Change Price Target Change
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Feb-22-24 07:00AM
Feb-21-24 11:16AM
Jan-30-24 09:35AM
Jan-22-24 08:48AM
07:00AM
12:00PM Loading…
Jan-18-24 12:00PM
Jan-03-24 12:00PM
08:10AM
Dec-15-23 07:56AM
07:22AM
Dec-05-23 05:59AM
Dec-01-23 07:00AM
Nov-28-23 07:33PM
Nov-20-23 06:00AM
Nov-07-23 07:00AM
08:37AM Loading…
Nov-03-23 08:37AM
07:00AM
Nov-02-23 07:00AM
Oct-27-23 07:00AM
Oct-24-23 09:40AM
Oct-23-23 10:00AM
Oct-20-23 10:00AM
Oct-18-23 08:26AM
Oct-17-23 07:00AM
Oct-05-23 07:00AM
Sep-05-23 01:09PM
08:48AM
07:00AM
Aug-04-23 08:15AM
07:14AM
07:00AM Loading…
07:00AM
Jul-28-23 07:00AM
Jul-26-23 07:00AM
Jul-03-23 07:00AM
Jun-30-23 03:13PM
Jun-27-23 07:00AM
Jun-23-23 04:30PM
Jun-16-23 10:45AM
May-04-23 09:02AM
Apr-28-23 07:14AM
07:00AM
Apr-26-23 08:01PM
Apr-07-23 08:29AM
Apr-05-23 07:00AM
Mar-20-23 08:00AM
Mar-16-23 07:00AM
Mar-08-23 07:00AM
Feb-07-23 07:00AM
Feb-02-23 08:15AM
Jan-27-23 09:57AM
Jan-26-23 07:00AM
Jan-18-23 07:00AM
Jan-07-23 08:45AM
Nov-30-22 07:00AM
Nov-25-22 07:17AM
Nov-23-22 07:30AM
Nov-08-22 07:58AM
Oct-29-22 08:06AM
Oct-28-22 09:25AM
08:00AM
Oct-04-22 08:36AM
Sep-26-22 07:30AM
Sep-01-22 08:00AM
Aug-24-22 04:05PM
Aug-11-22 07:30AM
Aug-02-22 11:00AM
Jul-31-22 08:12AM
Jul-28-22 08:45AM
07:30AM
Jul-22-22 07:30AM
Jun-24-22 04:30PM
Jun-21-22 10:35AM
Jun-17-22 08:31AM
Jun-16-22 08:20AM
06:39AM
01:00AM
Jun-01-22 08:26AM
May-31-22 07:30AM
May-17-22 09:00AM
May-09-22 11:00AM
Apr-28-22 07:30AM
Apr-27-22 07:55AM
Apr-08-22 07:30AM
Mar-30-22 07:58AM
Mar-22-22 07:30AM
Mar-21-22 07:30AM
Mar-16-22 07:41AM
Feb-28-22 07:30AM
Feb-21-22 04:30AM
Feb-15-22 02:54PM
07:30AM
Feb-04-22 07:30AM
Feb-02-22 08:58AM
Dec-15-21 07:49AM
Nov-15-21 06:01AM
Nov-12-21 08:21AM
Nov-10-21 11:20AM
Nov-08-21 08:25AM
07:00AM
Nov-07-21 07:53AM
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.